Myeloproliferative Disorders Clinical Trials

9 recruiting

Myeloproliferative Disorders Trials at a Glance

12 actively recruiting trials for myeloproliferative disorders are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Not Applicable with 4 trials, with the heaviest enrollment activity in Boston, Birmingham, and Chapel Hill. Lead sponsors running myeloproliferative disorders studies include Azienda Ospedaliero-Universitaria di Parma, UNC Lineberger Comprehensive Cancer Center, and University of Alabama at Birmingham.

Browse myeloproliferative disorders trials by phase

Treatments under study

About Myeloproliferative Disorders Clinical Trials

Looking for clinical trials for Myeloproliferative Disorders? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myeloproliferative Disorders trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myeloproliferative Disorders clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 1

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Acute LeukemiaMyelodysplastic SyndromesMyeloproliferative Disorders+3 more
Stanford University77 enrolled1 locationNCT05088356
Recruiting
Not Applicable

Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)

Acute LeukemiaChronic LeukemiaLymphoproliferative Disorders+2 more
Azienda Ospedaliero-Universitaria di Parma250 enrolled1 locationNCT07445984
Recruiting
Not Applicable

INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)

Pancreatic CancerOvarian CancerMelanoma+9 more
Azienda Ospedaliero-Universitaria di Parma300 enrolled2 locationsNCT07403630
Recruiting
Not Applicable

Prognostic Value of NETosis Markers for Thrombosis During Myeloproliferative Neoplasms (AVATARE)

Myeloproliferative DisordersMyeloproliferative Neoplasm
University Hospital, Bordeaux300 enrolled15 locationsNCT07119970
Recruiting
Phase 1

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

Acute Myeloid LeukemiaLeukemiaMyelodysplastic Syndromes+3 more
Dana-Farber Cancer Institute15 enrolled2 locationsNCT06138587
Recruiting

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

LymphomaLeukemiaMyelodysplastic Syndromes+5 more
UNC Lineberger Comprehensive Cancer Center15,000 enrolled1 locationNCT01137643
Recruiting
Phase 2

Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant

Myelodysplastic SyndromeAcute LeukemiaMyeloproliferative Disorders
University of Alabama at Birmingham56 enrolled1 locationNCT06265584
Recruiting
Phase 2

Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

Acute LeukemiaGVHD,AcuteMyelodysplastic Syndromes+1 more
University of Alabama at Birmingham29 enrolled1 locationNCT06315309
Recruiting
Not Applicable

I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients

LeukemiaMyeloproliferative Disorders
Massachusetts General Hospital30 enrolled3 locationsNCT05842603
Recruiting

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

LymphomaUnspecified Adult Solid Tumor, Protocol SpecificLeukemia+6 more
Barbara Ann Karmanos Cancer Institute1 locationNCT00935090
Recruiting

Registry of Older Patients With Cancer

LymphomaUnspecified Adult Solid Tumor, Protocol SpecificLeukemia+6 more
UNC Lineberger Comprehensive Cancer Center3,000 enrolled7 locationsNCT01137825
Recruiting
Phase 2

A multi-centre phase II, Australian and New Zealand, exploratory study of amendments to conditioning regimens in haplo-identical stem cell transplantation

transformed AML/ MDSMyeloproliferative DisordersHodgkin's Disease+4 more
St Vincent's Hospital, Sydney127 enrolled10 locationsACTRN12622001232729